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Introduction
Although all improved and labored treatment strategies to remedy of sepsis, it is still major cause of mortality and morbidity especially in the intensive care units with very high cost of treatment (Dellinger et al. 2013; Marik 2011) . In the past decades, major advances have been made in understanding the process and pathological mechanism of sepsis.
In early septic process, invasion of microorganisms into the bloodstream following mesenteric ischaemia leads to massive and uncontrolled release of the proinflammatory cytokines, especially tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), and free oxygen radicals (De Backer et al. 2014; Iskander et al. 2013; Yuksel et al. 2009 ).
TNF-α, the key mediator in sepsis, triggers the cascade of pathophysiological events in septic process including overproduction of the other cytokines such as IL-1β and IL-6, mitochondrial dysfunction, hypoxia, oxidative stress, intravascular coagulation, vasoplegia, multisystem hypoperfusion, severe sepsis (life-threatening organ dysfunction caused by a dysregulated host response to infection), septic shock (vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L in the absence of hypovolemia), multiple organ dysfunction syndrome (MODS) and even death (Duran-Bedolla et al. 2014; Ferro et al. 2000; Ley et al. 2007; Schulte et al. 2013; Singer et al. 2016) . It was shown that TNF-α inhibition has beneficial effects on the survival of Staphylococcal enterotoxin-induced septic shock in a mouse model (Fei et al. 2011) .
Infliximab is a human-murine chimeric monoclonal antibody against TNF-α that was approved for the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis, ankylosing spondylitis and rheumatoid arthritis (Lis et al. 2014) . It has also been reported that infliximab shows anti-inflammatory and antioxidant effects in a rat model of intestinal ischemia/reperfusion injury (Pergel et al. 2012 ).
In the light of these previous findings, we aimed to investigate the possible beneficial effects of infliximab pretreatment as a preventive strategy in an experimental model of sepsis induced by caecal ligation and puncture (CLP) with particular attention to the decreases in survival, mesenteric blood flow, contractile response of the aortic muscle to phenylephrine and as well as histopathological and biochemical injury in target vital organs such as liver, (Altintas et al. 2016; Saritemur et al. 2015) . All animals were fasted overnight but allowed ad libitum access to drinking water one day before the operations.
Twenty-nine animals were observed at 6-h intervals until 96 hours after the Sham and CLP operations for survival assessment. Twenty-four rats were used for mesenteric artery blood flow (MBF) and isometric measurements, histopathological and biochemical analyses. 
Polymicrobial sepsis model
Polymicrobial sepsis was induced by CLP operation as described previously (Hubbard et al. 2005; Ozer and Iskit 2016) . Briefly, rats were fasted overnight, but were allowed ad libitum access to drinking water one day before the operations. For the operation, the animals were anesthetized with chloral hydrate (400 mg/kg, i.p.) and a 2-cm ventral midline abdominal incision was performed. The cecum was then exposed, and ligated just below the ileocecal valve and punctured twice with an 18-gauge needle. The punctured cecum was gently massaged in order to expel a small amount of bowel feces and then abdominal incision was closed in two layers by using atraumatic 3-0 silk sutures. After the operation, normal saline (3 mL/100 g, subcutaneously) was injected immediately in rat's nape of the neck. For
Sham operation all of the same steps were performed, except for cecum ligation and puncture.
The rats that died during the surgery and within 20 hours after the Sham and CLP operations were excluded from the study. Several hours after CLP the animals showed clear symptoms of the disease, such as tachypnea, tachycardia, hypotension, hypothermia, piloerection, lethargy, hunched posture, diarrhea, anorexia, and behavioral changes.
Mesenteric artery blood flow measurement
After twenty hours the Sham and CLP operations rats were anesthetized with chloral hydrate and abdominal incision was performed again. The superior mesenteric artery was then carefully exposed and a perivascular Doppler ultrasonic probe was located around the artery in order to measure the blood flow. The Doppler flow probe was connected to a Transonic Small Animal Flowmeter System T206 (Transonic Inc., Ithaca, N.Y., USA), which provides blood flow readings (mL/min) absolutely. The rats were left to stabilize for 15 minutes before recording MBF values. The obtained signals from the flowmeter were also recorded on a computer by using a MP35 Biopac data recording system (Goleta, Calif., USA) (Yuksel et al. 2009 ).
Isometric measurements
The changes in alpha-receptor mediated vasoconstriction induced by CLP were evaluated on isolated rat aorta preparations by cumulative phenylephrine administration
which is an α 1 -receptor agonist into the organ bath. Thoracotomy was performed and thoracic part of aorta was then removed and put into the cold Krebs Henseleit (K-H) solution (as mM; sodium chloride 118, sodium bicarbonate 25, potassium chloride 4.7, calcium chloride 2, magnesium sulfate 1.2, monopotassium dihydrogen phosphate 1.2, and glucose 10) that gassed with carbogen (95% O 2 /5% CO 2 ). The isolated aorta was cautiously cleaned of surrounding fat and connective tissues and then 3 mm wide rings were obtained. The isolated aortic rings were mounted on two triangular stainless-steel wire specimen holders and transferred into the 20 mL isolated organ baths containing containing K-H solution that were kept at 37°C and aerated with carbogen. The aortic rings were adjusted to ~1 g resting tension and allowed to equilibrate in K-H solution for about 45 minutes with washing out of the tissues every 15 minutes (Ozer et al. 2015) . The muscle contractions were recorded using a force-displacement transducer and digitized data acquisition system (MP35 from BIOPAC, Goleta, California, USA). After this period phenylephrine (10 -9 to 3x 10 -5 Molar [M]) were applied into the organ baths with a cumulative concentration to study receptor mediated constriction. For each phenylephrine concentration, the increase in recorded contraction amplitude changes were expressed as grams of tension (Kalea et al. 2010; Kawabe et al. 2003 ). The obtained data were fit into a curve, and then EC50 value which is an indicator of potency and Emax value which is an indicator of efficacy were determined by using GraphPad Prism 5 software (GraphPad, UK).
Histopathological examination
The fixed tissue samples in 10% buffered formaldehyde solution were embedded in paraffin wax, sectioned at 5 µm thickness, mounted on slides, rehydrated, and then stained with hematoxylin and eosin (H&E) using standard methods. The blinded pathologist examined the tissue sections by the conventional Carl Zeiss Axio Lab.A1 light microscope and photographed majority of them using Axiocam MRc5 microscope camera.
Biochemical parameters
Before serum analysis, the frozen aliquots of serum samples were thawed and then mixed well. Serum levels of blood urea nitrogen (BUN) and creatinine (Cr), activities of lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured by using standard auto-analyzer methods on Abbott Architect 16000 system with the original reagents according to the manufacturer's instructions (Abbott Laboratories, Abbott Park, IL, USA). Hepatic dysfunction was evaluated by measurement the D r a f t increase of serum ALT (a specific marker for hepatic parenchymal injury) and serum AST (a nonspecific marker for liver damage). The levels of BUN and Cr (an indicator of reduced glomerular filtration rate and hence renal failure) were measured for the renal injury evaluation. LDH levels were measured for tissue damage, although not organ spesific.
As inflammatory markers, serum TNF-alpha (BMS622, eBioscience), IL-1beta (BMS630, eBioscience, San Diego, CA) and IL-6 (BMS625, eBioscience) levels were measured by using sandwich ELISA kits that were specifically designed for rat cytokines, and all measurements were made according to the manufacturer's instructions. Assays of each rat and its correlated control assay were run in the same lot.
MDA levels in liver, spleen, lung and renal tissues were assayed for evaluation of the All data were presented as mean ± standard deviation (mean ± SD) and analyzed with the GraphPad Prism 5 programme. All tests that were performed for statistical analyses were shown in the table and figure legends. The differences were considered to be significant when p<0.05. Some of the test parameters could not be evaluated in all rats because of the experimental procedure that were mentioned above. So, the "n" values for each subsections were separately given in the table and figure legends for different test parameters.
D r a f t

Results
Survival rates
96-hour survival rates are shown in Fig.1 
Mesenteric artery blood flow (MBF)
MBF values obtained from the anesthetized rats are shown in Fig.2 
Contractile response of aortic smooth muscle
CLP induced marked hyporesponsiveness to phenylephrine when compared with
Sham group (p<0.001) (Fig.3) , as shown by reductions in both pD2 (-logEC50 [M], potency)
and Emax values (maximal contractile effect, efficacy) for phenylephrine-induced contractions ( Table 1) . As shown in Table 1 , the infliximab pretreatment caused a greater increase in the phenylephrine potency of aortic rings in CLP+infliximab group (p<0.001 compared to CLP and p<0.01 compared to Sham). However, infliximab partially prevented the CLP-induced reduction in the maximal contractile effect to phenylephrine (p<0.05 compared to CLP and p<0.05 compared to Sham).
Biochemical results
The increases in the levels of serum AST, ALT, LDH, BUN and Cr, as well as TNF-α, IL-1β and IL-6 induced by CLP were totally prevented by infliximab (Table 2 and 3).
As shown in 
Histopathological Examinations
From the histopathological point of view, the structures of liver, lung, spleen and kidney samples were normal in the Sham and Sham+infliximab groups. However, CLP induced substantial histopathological alterations in these samples. In the septic liver tissues, there were moderate sinusoidal portal hemorrhage and mild inflammatory mononuclear cell infiltration in the parenchyma and periportal area (Fig.4-1C) . The septic lung tissues showed moderate intra-alveolar hemorrhage, hemosiderin-laden macrophages, mild interstitial and alveolar edema, as well as moderate peribronchial and interstitial inflammation that was concentrated near the vessel wall (Fig.4-2C ). The septic spleen tissues showed moderate hemorrhage, severe inflammation and also hemosiderin-laden macrophages (Fig.4-3C ). The moderate hemorrhage were observed in the septic kidney parenchyma (Fig.4-4C ). When the rats were treated with infliximab the lung (Fig.4-2D ) and spleen (Fig.4-3D ) architectures were greately improved and as well as liver (Fig.4-1D ) and kidney (Fig.4-4D ) tissues were completely prevented from the histopathological injuries induced by CLP.
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Discussion
In early sepsis, mesenteric perfusion is primarily impaired. Decrease of mesenteric blood flow leads to impaired intestinal barrier integrity and therefore translocation of microorganisms into the bloodstream. Spread of the microorganisms triggers massive and uncontrolled release of inflammatory cytokines and subsequent free radicals which ultimately causes negative effects on the vessels and multiple organs (Balzan et al. 2007; Erdem et al. 2007; Koh et al. 2002; Yuksel et al. 2009 ).
TNF-α is one of the first cytokines to be released in sepsis which amplifies the inflammatory response and oxidative stress (Qiu et al. 2011) . TNF-α also induces a vicious cycle promoting mesenteric hypoperfusion, vasoplegia and multiple organ dysfunction (Shimaoka and Park 2008) . Therefore, TNF-α inhibition may be an important and approachable therapeutic target for breaking the sepsis induced viscious cycle.
Infliximab is a TNF-α inhibitor which binds with high affinity to both the soluble and the transmembrane forms of TNF-α (Scallon et al. 2002) . Infliximab showed antiinflammatory and antioxidant effects in a rat model of intestinal ischemia/reperfusion injury and chronic inflammatory joint diseases such as ankylosing spondylitis and rheumatoid arthritis (Pergel et al. 2012; Tunez et al. 2007 ). Infliximab also showed benefical effects in an experimental model of endotoxin-induced uveitis (Yuksel et al. 2014) . Soluble TNFR II/IgG1
Fc fusion protein, a recombinant fusion protein that consists of the soluble TNF receptor (p75)
linked to the Fc portion of human IgG1 and a potent TNF-α inhibitor, protected against sepsis induced hypotension and death when administered 24 hours before endotoxin (lipopolysaccharide, LPS) challenge (Guo et al. 2009 ). Etanercept binds only to the trimer form of soluble TNF-α that is another TNF-α inhibitor, also improved the survival in a LPSinduced sepsis model (Lee et al. 2013) . These promising preclinical effects of TNF-α inhibitors have been shown especially in the endotoxemic rats. However, CLP is more reflective of the clinical reality for sepsis than previous animal models, such as injection of endotoxin or even purified bacteria into the rodents (Raven 2012) . Therefore, CLP model was choosen as an experimental sepsis model in this study. To the best of our knowledge, this is the first study that evaluates the possible benefical effects of infliximab on survival, mesenteric blood flow, contractile function of aorta, multiple organ injury after CLP.
In our study, we found that the infliximab administration decreased the mortality, attenuated the mesenteric hypoperfusion, prevented the vascular hyporesponsiveness in the isolated aortic rings, reduced plasma levels of biochemical parameters and as well as D r a f t ameliorated histopathological changes in CLP-induced septic rats. This study provides novel evidence that pretreatment with infliximab seems to improve the survival in the CLP-induced septic rats as a consequence of reduced dysfunction/injury of multiple organs and vessels.
These protective effects could be due to attenuation of TNF-α (mainly), IL-1β and IL-6 productions, suppression of oxidative stress, prevention of the mesenteric hypoperfusion and vasoplegia by infliximab. Most of the therapeutic effects of infliximab in septic animals were firstly shown in this study. According to our results some patient groups such as patients with immunosuppression, humans in extremes of age (neonates or elderly) have increased risk for the development of sepsis and infliximab may be given for prophylactic agent.
Conclusion
In conclusion, our results show that infliximab has protective effect against sepsisinduced mortality and MODS due to improvements of mesenteric hypoperfusion and contractile dysfunction of aorta and its antiinflammatory and antioxidative effects in septic rats. This study is primarily focused on demonstrating the beneficial and protective effects of ant-TNF therapy on prior to sepsis via using a septic animal model. Sham+infliximab group (a, p<0.05; bb,cc, p<0.01; aaa,bbb,ccc, p<0.001) . (Fig.4-1A) , lung (Fig.4-2A) , spleen (Fig.4-3A) and kidney (Fig.4-4A ) tissues showed normal histopathological structure. There were also normal liver (Fig.4-1B) , lung (Fig.4-2B ), spleen ( Fig.4-3B ) and kidney (Fig.4-4B ) tissues in the Sham+infliximab group. Fig.4-1C ;
septic liver tissue with moderate sinusoidal portal hemorrhage (arrowhead) and mild inflammatory mononuclear cell infiltration in the parenchyma and periportal area (arrow). Fig.4-1D ; normal liver architecture in CLP+infliximab group. Fig.4-2C ; the septic lung tissue with moderate intra-alveolar hemorrhage (arrowhead), hemosiderin-laden macrophages (4-point star) and as well as moderate peribronchial and interstitial inflammation that was D r a f t 19 concentrated near the vessel wall (arrow). Fig.4-2D ; the reduced lung injury in CLP+infliximab group with little inflammation (arrow). Fig.4-3C ; septic spleen tissue with moderate hemorrhage (arrowhead), severe inflammation (arrow), hemosiderin-laden macrophages (4-point star). Fig.4-3D ; the reduced spleen injury in CLP+infliximab group with little hemorrhage (arrowhead) and inflammation (arrow). Fig.4-4C ; septic kidney tissue with moderate hemorrhage (arrowhead). Fig.4-4D 62x44mm (600 x 600 DPI)
